Constarium
← Search

Data · dataset · 2024

Infant Protection Against Respiratory Syncytial Virus (RSV) by Maternal RSV Vaccination or Receipt of Nirsevimab, and Intent for Nirsevimab Receipt, United States

Listed in data.cdc.gov

Description

Infant Protection Against RSV by Maternal RSV Vaccination or Receipt of Nirsevimab and Intent for Nirsevimab Receipt, Reported by Females Aged 18-49 Years Who Have an Infant <8 Months During the RSV Season (born since April 1, 2024) Monthly estimates of infant protection against RSV by maternal RSV vaccination or receipt of nirsevimab, as well as intent for nirsevimab receipt, were calculated using data from the from the National Immunization Survey–Adult COVID Module (NIS–ACM).

(cdc.gov/nis/about/index.html). Data were reported by adult females aged 18-49 years with infants under the age of 8 months during the RSV season (born since April 1, 2024). The NIS–ACM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older.

Read the rest (1 more)

All estimates are based upon parent-reported receipt of nirsevimab.

Links

Topics

Stated by source
Pregnancy & Vaccination
From keywords
Medicine & Health
Provenance · 1 source records, 9 field assertions
SourceKeyLast seenRaw
data.cdc.govvdz4-qrri11 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · data cdc govconnector:data_cdc_gov@1.0.0
concepts[field].local:field:medicine-healthmapping · data cdc govconnector:data_cdc_gov@1.0.0
concepts[topic].socrata_category:data_cdc_gov:pregnancy-vaccinationsource · data cdc govconnector:data_cdc_gov@1.0.0
created_datesource · data cdc govconnector:data_cdc_gov@1.0.0
descriptionsource · data cdc govconnector:data_cdc_gov@1.0.0/resource/description
license_textsource · data cdc govconnector:data_cdc_gov@1.0.0
publication_datesource · data cdc govconnector:data_cdc_gov@1.0.0
titlesource · data cdc govconnector:data_cdc_gov@1.0.0/resource/name
updated_datesource · data cdc govconnector:data_cdc_gov@1.0.0